Physician profile
David C Marsh
NPI 1588627822
$6,312.10
in general payments reported to CMS, 2019-2025
23 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $956 · 2022: $1,277 · 2023: $864 · 2024: $1,310 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,910.48 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.53 | 2021-2025 | |
| Janssen Biotech, INC. | $763.80 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $731.49 | 2021-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $719.52 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $457.17 | 2021-2025 | Entyvio, Eohilia |
| Celgene Corporation | $372.70 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $264.49 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $215.82 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $200.48 | 2024-2025 | Zenpep |
| Pfizer INC. | $179.82 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $124.59 | 2023-2024 | Rebyota |
| Lilly USA, LLC | $99.89 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $82.91 | 2021-2024 | Suflave, Sutab |
| Novo Nordisk INC | $67.19 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $57.52 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $41.27 | 2022 | |
| Intercept Pharmaceuticals, INC. | $33.18 | 2021-2022 | |
| Medtronic, INC. | $20.05 | 2025 | Pillcam |
| Nestle Healthcare Nutrition INC. | $19.81 | 2023 | |
| Echosens North America, INC. | $15.83 | 2024 | Fibroscan |
| Amgen INC. | $15.61 | 2022 | |
| Redhill Biopharma INC. | $13.17 | 2022 | |
| Evoke Pharma, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.